Suicidality in children and adolescents

Suicidality in children and adolescents, neurobiological parameters, and their mutual association.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16781226

Enrollment

Registered

2025-06-16

Start date

2025-02-01

Completion date

Unknown

Last updated

2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incidence of suicide attempts in the last seven days, Incidence of suicidal ideations. Mental and Behavioural Disorders

Interventions

The research group will consist of 60 patients who will be divided into two groups: patients with suicidal ideations (SI) and patients after suicide attempts (SA). The enrolled patients will be asked

Eligibility

Sex/Gender

All

Age

10 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Patients hospitalized at the Department of Paediatric Psychiatry of the Comenius University, Medical Faculty and the National Institute of Children's Diseases, age 10-17 years. 2. Signed informed consent by the legal guardian. 3. Verbal consent of the patient to be included in the project. 4. Presence of suicidal ideation and/or suicide attempts. 5. Children and adolescents are willing to provide blood, urine, and hair samples.

Exclusion criteria

Exclusion criteria: Chronic somatic inflammatory and oncological disease

Design outcomes

Primary

Measure	Time frame
1. Prevalence of suicidal ideation is measured using the self-report Symptom Checklist 90 (SCL90R) at a single time point 2. Prevalence of suicide attempts is measured using the self-report Symptom Checklist 90 (SCL90R) at a single time point 3. Depressive symptoms severity is measured using the Children's Depression Rating Scale Revised (CDRSR) at a single time point 4. Suicide risk is measured using the Columbia Suicide Severity Rating Scale (CSSRS) at a single time point 5. Depressive symptoms in children and adolescents are measured using the Child Depression Inventory (CDI) self-report questionnaire at a single time point 6. Childhood adversity is measured using the self-report Yale Vermont Adversity in Childhood Scale (YVACSSR) at a single time point 7. Impact of COVID-19 on mental health is measured using the self-report COVID-19 Yorkshire Rehabilitation Scale (C19YRS) at a single time point 8. Mental health evaluation in healthy controls is measured using the Children's Depression Rating Scale Revised (CDRSR) at a single time point	—

Measure

Time frame

1. Prevalence of suicidal ideation is measured using the self-report Symptom Checklist 90 (SCL90R) at a single time point 2. Prevalence of suicide attempts is measured using the self-report Symptom Checklist 90 (SCL90R) at a single time point 3. Depressive symptoms severity is measured using the Children's Depression Rating Scale Revised (CDRSR) at a single time point 4. Suicide risk is measured using the Columbia Suicide Severity Rating Scale (CSSRS) at a single time point 5. Depressive symptoms in children and adolescents are measured using the Child Depression Inventory (CDI) self-report questionnaire at a single time point 6. Childhood adversity is measured using the self-report Yale Vermont Adversity in Childhood Scale (YVACSSR) at a single time point 7. Impact of COVID-19 on mental health is measured using the self-report COVID-19 Yorkshire Rehabilitation Scale (C19YRS) at a single time point 8. Mental health evaluation in healthy controls is measured using the Children's Depression Rating Scale Revised (CDRSR) at a single time point

—

Secondary

Measure	Time frame
1. Total cholesterol is measured using standard methods in a commercial clinical laboratory at a single time point 2. LDL cholesterol is measured using standard methods in a commercial clinical laboratory at a single time point 3. HDL cholesterol is measured using standard methods in a commercial clinical laboratory at a single time point 4. ApoA is measured using standard methods in a commercial clinical laboratory at a single time point 5. ApoE is measured using standard methods in a commercial clinical laboratory at a single time point 6. hsCRP is measured using standard methods in a commercial clinical laboratory at a single time point 7. IL6 is measured using standard methods in a commercial clinical laboratory at a single time point 8. IL2 is measured using standard methods in a commercial clinical laboratory at a single time point 9. Fibrinogen is measured using standard methods in a commercial clinical laboratory at a single time point 10. Orosomucoid is measured using standard methods in a commercial clinical laboratory at a single time point 11. Neutrophil count is measured using standard methods in a commercial clinical laboratory at a single time point 12. Lymphocyte count is measured using standard methods in a commercial clinical laboratory at a single time point 13. Neutrophil to lymphocyte ratio is measured using standard methods in a commercial clinical laboratory at a single time point 14. LDL subfractions are measured using the Lipoprint system at a single time point 15. HDL subfractions are measured using the Lipoprint system at a single time point 16. BDNF is measured using Elisa kit at a single time point 17. Nrf2 is measured using Elisa kit at a single time point 18. Lipoperoxides are measured using spectrophotometry at a single time point 19. AOPP is measured using spectrophotometry at a single time point 20. Catalase activity is measured using spectrophotometry at a single time point 21. SOD activity is measured using kits in erythrocyte hem	—

Measure

Time frame

1. Total cholesterol is measured using standard methods in a commercial clinical laboratory at a single time point 2. LDL cholesterol is measured using standard methods in a commercial clinical laboratory at a single time point 3. HDL cholesterol is measured using standard methods in a commercial clinical laboratory at a single time point 4. ApoA is measured using standard methods in a commercial clinical laboratory at a single time point 5. ApoE is measured using standard methods in a commercial clinical laboratory at a single time point 6. hsCRP is measured using standard methods in a commercial clinical laboratory at a single time point 7. IL6 is measured using standard methods in a commercial clinical laboratory at a single time point 8. IL2 is measured using standard methods in a commercial clinical laboratory at a single time point 9. Fibrinogen is measured using standard methods in a commercial clinical laboratory at a single time point 10. Orosomucoid is measured using standard methods in a commercial clinical laboratory at a single time point 11. Neutrophil count is measured using standard methods in a commercial clinical laboratory at a single time point 12. Lymphocyte count is measured using standard methods in a commercial clinical laboratory at a single time point 13. Neutrophil to lymphocyte ratio is measured using standard methods in a commercial clinical laboratory at a single time point 14. LDL subfractions are measured using the Lipoprint system at a single time point 15. HDL subfractions are measured using the Lipoprint system at a single time point 16. BDNF is measured using Elisa kit at a single time point 17. Nrf2 is measured using Elisa kit at a single time point 18. Lipoperoxides are measured using spectrophotometry at a single time point 19. AOPP is measured using spectrophotometry at a single time point 20. Catalase activity is measured using spectrophotometry at a single time point 21. SOD activity is measured using kits in erythrocyte hem

—

Countries

Slovakia

Contacts

Public ContactJana Trebatická

jana.trebaticka@fmed.uniba.sk+421 905560219

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Sep 19, 2026